A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Interventions: DRUG: SHR-A1811|DRUG: Trastuzumab Emtansine
Sponsor: Jiangsu HengRui Medicine Co., Ltd.